Vanguard Personalized Indexing Management LLC Acquires 1,778 Shares of Cencora, Inc. $COR

by · The Markets Daily

Vanguard Personalized Indexing Management LLC grew its holdings in shares of Cencora, Inc. (NYSE:COR – Free Report) by 5.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 35,661 shares of the company’s stock after acquiring an additional 1,778 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Cencora were worth $12,045,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. AustralianSuper Pty Ltd bought a new position in shares of Cencora during the third quarter valued at $26,191,000. Chilton Investment Co. Inc. bought a new position in shares of Cencora during the third quarter valued at $459,000. Lansforsakringar Fondforvaltning AB publ increased its position in shares of Cencora by 5.4% during the third quarter. Lansforsakringar Fondforvaltning AB publ now owns 60,254 shares of the company’s stock worth $18,831,000 after buying an additional 3,073 shares during the period. Nordea Investment Management AB increased its position in shares of Cencora by 3.8% during the fourth quarter. Nordea Investment Management AB now owns 1,256,356 shares of the company’s stock worth $426,715,000 after buying an additional 45,712 shares during the period. Finally, Assetmark Inc. increased its position in shares of Cencora by 57.0% during the fourth quarter. Assetmark Inc. now owns 67,281 shares of the company’s stock worth $22,724,000 after buying an additional 24,431 shares during the period. Institutional investors own 97.52% of the company’s stock.

Cencora Trading Down 0.0%

COR opened at $281.58 on Tuesday. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. The company has a market cap of $54.78 billion, a P/E ratio of 21.59, a price-to-earnings-growth ratio of 1.52 and a beta of 0.59. The company has a fifty day moving average price of $288.36 and a two-hundred day moving average price of $326.67.

Cencora (NYSE:COR – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The firm had revenue of $78.36 billion for the quarter, compared to analyst estimates of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The firm’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same period last year, the company posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Analysts predict that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora announced that its board has initiated a stock repurchase plan on Thursday, May 21st that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to reacquire up to 3.9% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s management believes its stock is undervalued.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s dividend payout ratio is presently 18.40%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Citigroup decreased their price objective on shares of Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Leerink Partners reiterated an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. UBS Group increased their price objective on shares of Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Morgan Stanley set a $342.00 price objective on shares of Cencora in a research report on Friday, May 8th. Finally, Barclays decreased their price objective on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research report on Wednesday, June 10th. Twelve investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $374.00.

View Our Latest Research Report on Cencora

Cencora Company Profile

(Free Report)

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

Featured Stories

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).